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Povel Metabolic Risk Factors for Heart Failure
rik Ingelsson, MD, PHD,* Johan A¨rnlöv, MD, PHD,* Johan Sundström, MD, PHD,*
jörn Zethelius, MD, PHD,* Bengt Vessby, MD, PHD,* Lars Lind, MD, PHD†‡
ppsala and Mölndal, Sweden
OBJECTIVES Our objectives were to explore novel metabolic risk factors for development of heart failure
(HF).
BACKGROUND In the past decade, considerable knowledge has been gained from limited samples regarding
novel risk factors for HF, but the importance of these in the general population is largely
unexplored.
METHODS In a community-based prospective study of 2,321 middle-aged men free from HF and
valvular disease at baseline, variables reflecting glucose and lipid metabolism and variables
involved in oxidative processes were compared with established risk factors for HF (prior
myocardial infarction, hypertension, diabetes, electrocardiographic left ventricular hypertro-
phy, smoking, obesity, and serum cholesterol) using Cox proportional hazards analyses.
RESULTS During a median follow-up time of 29 years, 259 subjects developed HF. In a multivariable
Cox proportional hazards backward stepwise model, a 1-SD increase of fasting proinsulin
(hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.15 to 1.66) and apolipoprotein
B/A-I-ratio (HR 1.27, 95% CI 1.09 to 1.48) increased the risk, whereas a 1-SD increase in
serum beta-carotene (HR 0.79, 95% CI 0.66 to 0.94) decreased the risk of HF. These
variables also remained significant when adjusting for acute myocardial infarction during
follow-up.
CONCLUSIONS Novel variables reflecting insulin resistance and dyslipidemia, together with a low beta-
carotene level, were found to predict HF independently of established risk factors. If
confirmed, our observations could have large clinical implications, as they may offer new
approaches in the prevention of HF. (J Am Coll Cardiol 2005;46:2054–60) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.059American College of Cardiology Foundation
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teart failure (HF), a major cause of morbidity and mortal-
ty, is reported to consume 1% to 2% of the total health care
osts in industrialized countries (1). The age-adjusted mor-
ality for HF patients is four to eight times to that of the
eneral population (2), comparable to that of cancer diseases
n the same age groups (3). Therefore, the identification
f potentially modifiable risk factors for HF is of great
mportance.
The predominant causes of HF are hypertension and
oronary heart disease (CHD). Other identified risk factors
or HF include left ventricular (LV) hypertrophy, valvular
eart disease, diabetes mellitus, cigarette smoking, obesity,
nd dyslipidemia (2,4–8). Population-based studies to date
ave shown different results concerning the relative impor-
ance of these risk factors. In the past decade, considerable
nowledge has been gained regarding the pathophysiology
f HF in the experimental setting, small clinical samples,
nd larger population-based studies. New mechanisms, such
s insulin resistance (9,10), inflammation (11,12), and
xidative stress (13–15), have been investigated, but the
mportance of many of these mechanisms is largely unex-
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rticle.n
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ccepted July 25, 2005.lored in the general population. Epidemiologic studies
nvestigating the importance of novel risk factors for HF are
herefore highly motivated.
Our primary aim was to analyze established and novel risk
actors for development of HF in a community-based sample
f middle-aged men. As several of the risk factors identified
or HF also are risk factors for CHD, a secondary aim was
o analyze whether the risk factors predicted HF indepen-
ently of an interim myocardial infarction (MI) during the
ollow-up.
ETHODS
tudy sample. The study is based on the Uppsala Longi-
udinal Study of Adult Men (ULSAM) cohort, a health
nvestigation focusing at identifying metabolic risk factors
or cardiovascular disease, to which all 50-year-old men
iving in Uppsala in 1970 to 1974 were invited. Of these,
2% (2,322 men) participated in the investigation (16). In
ddition to regular re-examinations, the data have been
ompleted with annual updates on mortality and in-hospital
orbidity using national registers. The ULSAM trial is
escribed in detail on the Internet (17). One subject was
xcluded because of valvular disease at baseline; thus, 2,321
en were eligible for the investigation. All subjects gave
ritten consent, and the ethics committee of Uppsala
niversity approved the study.
xaminations at baseline. Examinations, performed when
he subjects were 50 years old, included a medical exami-
ation, a questionnaire, blood sampling (after an overnight
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December 6, 2005:2054–60 Novel Risk Factors for HFast) with fasting and 60-min blood glucose and plasma
nsulin concentrations after an intravenous glucose tolerance
est (IVGTT), supine blood pressure, pulse rate, and an-
hropometric measurements as previously described (16).
he concentrations of intact and 32-33 split proinsulin were
nalyzed in 1995 to 1998 by a two-site immunometric assay
echnique (18). Because of a freezer failure, proinsulin-like
olecules were determined in baseline plasma samples from
,306 of the subjects. Homeostasis model assessment
HOMA) insulin resistance index was calculated using fasting
lasma glucose and insulin concentrations by the formula:
asting insulin · fasting glucose/22.5 (19). The methods of lipid
eterminations have been extensively described (20). Apo(a)
nd ApoB were determined by a two-site immuno-radiometric
ssay and ApoA-I by a competitive radioimmunoassay. Alpha
ocopherol and beta-carotene were simultaneously determined
y high-performance liquid chromatography (21). The serum
ocopherol concentrations as reported are corrected for the sum
f serum cholesterol and serum triglycerides [tocopherol/
cholesteroltriglyceride)] (22). Uric acid in serum was
easured by spectrophotometry.
The presence of hypertension at baseline was defined as
ystolic blood pressure 140 mm Hg and/or diastolic blood
ressure 90 mm Hg or anti-hypertensive medication. The
resence of diabetes at baseline was defined as fasting blood
lucose 6.1 mmol/l and/or the use of oral hypoglycemic
gents or insulin. Electrocardiographic left ventricular hy-
ertrophy (ECG-LVH) was defined as high-amplitude R
aves according to the revised Minnesota code (23), to-
ether with LV strain pattern (4). The presence of valvular
isease (International Classification of Diseases [ICD]-8
odes 394-396 and 424, ICD-9 codes 394-397 and 424 or
CD-10 codes I05-I08 and I34-I37) and prior MI (ICD-8
ode 410, ICD-9 code 410, or ICD-10 code I21) were
ssessed from the hospital discharge register. The diagnosis
f acute MI was chosen as a proxy for CHD, as the
recision of the MI diagnosis in the Swedish hospital
Abbreviations and Acronyms
BMI  body mass index
CHD  coronary heart disease
CI  confidence interval
ECG-LVH  electrocardiographic left ventricular
hypertrophy
HDL  high-density lipoprotein
HF  heart failure
HOMA  homeostasis model assessment
HR  hazard ratio
ICD  International Classification of Diseases
IVGTT  intravenous glucose tolerance test
LDL  low-density lipoprotein
LV  left ventricular
MI  myocardial infarction
ULSAM  Uppsala Longitudinal Study of Adult Menischarge register is high (24,25). Furthermore, adjusting 4or or excluding interim MI is an established method for
xamining “non-ischemic” HF (26,27).
ollow-up and outcome parameter. The subjects had a
edian follow-up time of 28.8 years (range 0.04 to 31.7
ears), contributing to 58,084 person-years at risk. A total of
21 men had a hospital discharge register diagnosis of HF
etween the entry to the ULSAM trial and the end of 2001.
s a possible diagnosis of HF, we considered ICD HF
odes 427.00, 427.10, 428.99 (ICD-8), 428 (ICD-9), I50
ICD-10) and hypertensive heart disease with HF, I11.0
ICD-10). The medical records from the relevant hospital-
zation were reviewed by two physicians (E.I. and L.L.),
linded to the baseline data, who classified the cases as
efinite, questionable, or miscoded. The classification relied
n the definition proposed by the European Society of
ardiology (28), and the review process has been described
xtensively (29). After this validation, 259 cases of definite
F were included in the present study. A total of 840
ubjects (36%) died during follow-up. None of the subjects
ere lost to follow-up.
tatistical methods. Data are given as percentages for cate-
orical variables, means  SD for normal distributed con-
inuous variables or medians (interquartile range) for skewed
ariables. Logarithmic transformation was performed to
chieve normal distribution for the skewed variables
IVGTT s-insulin 60 min, fasting insulin, fasting proinsu-
in, fasting split proinsulin, high-density lipoprotein [HDL]
holesterol, apo(a), serum triglycerides and beta-carotene).
he residuals of all regression analyses were examined and
ound to be normally distributed. Persons who developed
nd did not develop HF during follow-up were compared at
aseline with Kruskal-Wallis tests (skewed continuous vari-
bles), t tests (normal distributed continuous variables), or
hi-square analyses (categorical variables). The prognostic
alues of a one-standard deviation increase in the continu-
us variables, or transfer from one level to another for the
ichotomous variables, for HF incidence were investigated
ith Cox proportional hazards analyses. Proportionality of
azards was confirmed by visually examining Nelson-Aalen
urves. Nonlinear relations were excluded by examining
ncidence rates in quartiles of the independent variables. We
sed four sets of models in a hierarchical fashion:
. Unadjusted analyses.
. Analyses adjusted for the following known risk factors:
prior acute MI, hypertension, diabetes, ECG-LVH,
smoking, body mass index (BMI), and serum choles-
terol.
. Novel variables significant in models 1 and 2 were then
included in a multivariable Cox proportional hazards
backward stepwise model together with the established
risk factors in order to evaluate the independency
between different novel variables. A level of p  0.05
was used for exclusion.. As in model 3 with addition of interim MI.
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Novel Risk Factors for HF December 6, 2005:2054–60An analysis of the interaction terms between interim MI
nd significant variables in model 4 was performed. All the
bove analyses were repeated in a subsample without sub-
ects with prior MI at baseline or MI during follow-up.
ecause fasting insulin, proinsulin, and split proinsulin were
nalyzed in only 55% of the cohort, we excluded these
ariables in secondary analyses of models 3 and 4 in order to
roduce a larger sample. Two-tailed 95% confidence inter-
als and p values were given, with p  0.05 regarded as
ignificant. Statistical software package STATA 8.2 (Stata
orp., College Station, Texas) was used.
ESULTS
he incidence rate for HF during the follow-up period was
.5/1,000 person-years at risk. Table 1 shows the clinical
haracteristics at baseline of subjects with and without
ncident HF during follow-up.
In unadjusted Cox proportional hazards analyses, estab-
ished risk factors for HF, as well as several novel variables,
ere significant predictors of HF incidence (Table 2,
iddle column). When adjusting for established risk factors
or HF (prior acute MI, hypertension, diabetes, ECG-
VH, smoking, BMI, and serum cholesterol), fasting intact
Table 1. Baseline Clinical Characteristics of th
Remained Free From or Developed Heart Fail
Total C
(n  2
Glucometabolic variables
IVGTT b-glucose 60 min (mmol/l) 11.3 
IVGTT s-insulin 60 min (U/ml) 24.3 (15.
Fasting insulin (pmol/l) 41 (28–
Fasting proinsulin (pmol/l) 2.3 (1.4
Fasting split proinsulin (pmol/l) 5.7 (3.7
HOMA-insulin resistance 3.0 
Lipometabolic variables
HDL cholesterol (mmol/l) 1.3 (1.1
LDL cholesterol (mmol/l) 5.3 
Apo(a) (U/l) 119 (49–
Apolipoprotein B/A-I-ratio 0.89 
S-triglycerides (mmol/l) 1.7 (1.3
Oxidative stress variables
Alpha tocopherol (mg/l) 1.50 
Beta-carotene (g/l) 135 (91–
S-uric acid (mg/100 ml) 4.3 
Established risk factors for HF
Prior acute myocardial infarction 7 (0.3
Hypertension prevalence 990 (43)
Diabetes prevalence 132 (6)
ECG-LVH 40 (1.7
Current cigarette smoking 1184 (51)
BMI (kg/m2) 25.0 
S-cholesterol (mmol/l) 6.9 
Data described as medians (interquartile range) for all ske
proinsulin, fasting split proinsulin, HDL cholesterol, apo(a),
other continuous variables. Data for categorical variables are
who developed and did not develop HF during follow-up
continuous variables), t tests (normal distributed continuous
†p  0.01, ‡p  0.001.
BMI body mass index; ECG-LVH electrocardiograp
HF  heart failure; HOMA  homeostasis model assessment
low-density lipoprotein.roinsulin, fasting 32-33 split proinsulin, HOMA-insulin
esistance, HDL cholesterol, apolipoprotein B/A-I-ratio,
nd beta-carotene remained significant predictors of HF
Table 2, right column).
These variables were included in a multivariable Cox
roportional hazards backward stepwise model together
ith the established risk factors. In this analysis, fasting
roinsulin, apolipoprotein B/A-I-ratio, beta-carotene (pro-
ective), hypertension, BMI, and ECG-LVH were inde-
endent predictors of HF (Table 3). When we adjusted for
he incidence of acute MI during follow-up, all these six
ariables remained independent predictors of HF (Fig. 1A).
umulative incidence plots for values above and below the
edian value of the first three of these variables are
resented in Figure 2. Evidence of MI during the follow-up
as present in 409 of the subjects in the total cohort and in
8 of the 259 HF cases (38%). In an unadjusted Cox
roportional hazards analysis, an interim MI was a signifi-
ant predictor of HF (hazard ratio [HR] 3.50, 95% confi-
ence interval [CI] 2.72 to 4.50, p  0.001).
As there was a significant interaction between ECG-
VH and interim MI, and a borderline significant interac-
ion between hypertension and interim MI, we performed a
tal Cohort and Groups of Persons Who
uring Follow-Up
t Did Not Develop HF
(n  2,062)
Developed HF
(n  259)
11.2  3.1 11.7  3.7
0) 24.1 (15.7–35.4) 25.7 (15.5–42.2)
40 (28–61) 49 (33–75)‡
2.2 (1.4–3.6) 3.1 (1.7–4.8)‡
5.6 (3.7–8.7) 6.8 (4.6–11.0)‡
2.8  1.8 3.9  3.3‡
1.3 (1.1–1.6) 1.2 (1.1–1.5)†
5.3  1.2 5.5  1.4†
115 (48–317) 138 (64–421)
0.88  0.26 0.97  0.28‡
1.6 (1.3–2.2) 1.8 (1.4–2.5)‡
1.50  0.26 1.50  0.26
137 (93–202) 118 (79–184)†
4.3  1.0 4.5  1.1*
5 (0.2) 2 (0.8)
833 (40) 157 (61)‡
109 (5) 23 (9)*
26 (1.3) 14 (5.4)‡
1039 (50) 145 (56)
24.9  3.1 26.4  3.5‡
6.9  1.3 7.1  1.4*
ariables (IVGTT s-insulin 60 min, fasting insulin, fasting
cerides and beta-carotene) and as mean values  SD for the
as a number of cases, with percentages in brackets. Persons
compared at baseline with Kruskal-Wallis tests (skewed
es), or chi-square analyses (categorical variables). *p  0.05,
ft ventricular hypertrophy; HDL high-density lipoprotein;e To
ure D
ohor
,321)
3.2
7–36.
62)
–3.7)
–8.8)
2.0
–1.6)
1.3
320)
0.26
–2.2)
0.26
200)
1.0
)
)
3.2
1.3
wed v
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December 6, 2005:2054–60 Novel Risk Factors for HFecondary analysis in a subsample, excluding persons with
I before baseline or during follow-up. In a multivariable
ox proportional hazards analysis in this subgroup using the
ix independently significant predictors of HF defined in
he total cohort, the point estimates remained essentially
he same except for ECG-LVH, but with somewhat wider
Is (Fig. 1B).
In secondary analyses, excluding the insulin-like molecule
ariables, we obtained essentially the same results as in the
revious analyses that included these variables. However,
hen fasting proinsulin was removed from the multivariable
odel, HOMA-insulin resistance and smoking were in-
luded as significant predictors of HF in the final model
HR 1.29, 95% CI 1.09 to 1.53, p  0.004 for a 1-SD
ncrease and HR 1.55, 95% CI 1.10 to 2.18, p  0.012 for
mokers vs. nonsmokers).
ISCUSSION
rincipal findings. In this community-based cohort study
Table 2. Heart Failure Morbidity in Relation t
Total Sample (n  2,321)
H
Glucometabolic variables
IVGTT b-glucose 60 min (mmol/l)
IVGTT s-insulin 60 min (U/ml)
Fasting insulin (pmol/l)
Fasting proinsulin (pmol/l)
Fasting split proinsulin (pmol/l)
HOMA-insulin resistance
Lipometabolic variables
HDL cholesterol (mmol/l)
LDL cholesterol (mmol/l)
Apo(a) (U/l)
Apolipoprotein B/A-I-ratio
S-triglycerides (mmol/l)
Oxidative stress variables
Alpha tocopherol (mg/l)
Beta-carotene (g/l)
S-uric acid (mg/100 ml)
Established risk factors for HF
Prior acute myocardial infarction
Hypertension prevalence
Diabetes prevalence
ECG-LVH
Current cigarette smoking
BMI (kg/m2)
S-cholesterol (mmol/l)
Presented as unadjusted data and adjusted for established risk
proportional hazards ratios are given for a 1-SD increase
dichotomous variables where the hazard ratios reflect a transfe
intervals), crude or adjusted for established risk factors (prior
smoking, BMI, and serum cholesterol). The values shown fo
multivariable model incorporating only these variables. p values
CI  confidence interval; other abbreviations as in Tablef middle-aged men with a median follow-up time of 29 rears, we identified novel variables reflecting insulin resis-
ance, an increased apolipoprotein B/A-I ratio and a low
ntioxidant level (beta-carotene) to be risk factors for HF,
ndependent of MI and other established risk factors for HF.
revious established risk factors. Previous studies have
hown that the predominant causes of HF are hypertension
nd CHD, and this was confirmed in the present study. In
ur sample, 61% of the subjects who developed HF were
ypertensive at baseline and 38% of the cases had a history
f MI. This corresponds to the observations of other
ommunity-based studies (30). The risk for HF associated
ith hypertension is further captured in the ECG-LVH
ariable as previously described (4). Along with hyperten-
ion, LV hypertrophy, and MI, all the previous established
isk factors for HF (2,4–8) were significant predictors of
F also in the ULSAM trial.
arkers of impaired glucose regulation. We observed
hat markers of impaired insulin secretion and insulin
esistance were independently associated with an increased
tablished and Novel Risk Factors in the
justed Values
Adjusted for
Established
Risk Factors
d Ratio for HF
rresponding
-SD Increase
(95% CI)
Hazard Ratio for HF
Corresponding
to a 1-SD Increase
(95% CI)
(1.06–1.41)† 0.98 (0.84–1.14)
(1.05–1.41)† 0.96 (0.84–1.10)
(1.25–1.69)‡ 1.14 (0.95–1.37)
(1.41–1.92)‡ 1.38 (1.15–1.64)‡
(1.37–1.86)‡ 1.28 (1.07–1.54)†
(1.37–1.79)‡ 1.16 (1.00–1.35)*
(0.70–0.92)‡ 0.86 (0.74–0.99)*
(1.09–1.39)‡ 1.57 (0.89–2.80)
(0.99–1.31)
(1.26–1.61)‡ 1.31 (1.11–1.54)‡
(1.23–1.54)‡ 1.07 (0.93–1.22)
(0.83–1.08)
(0.66–0.86)‡ 0.86 (0.74–0.99)*
(1.04–1.32)* 1.02 (0.90–1.16)
(1.12–18.14)* 3.37 (0.83–13.63)
(1.91–3.14)‡ 1.93 (1.48–2.52)‡
(1.24–2.92)† 1.61 (1.05–2.48)*
(3.31–9.77)‡ 4.43 (2.55–7.69)‡
(1.16–1.89)† 1.76 (1.37–2.26)‡
(1.44–1.79)‡ 1.47 (1.31–1.65)‡
(1.07–1.35)† 1.12 (0.99–1.26)
rs (only for variables significant in unadjusted analysis). Cox
or logarithmically transformed variables, except for the
normal to abnormal. Data are hazard ratios (95% confidence
myocardial infarction, hypertension, diabetes, ECG-LVH,
lished risk factors in the right column are acquired from a
ere considered significant. *p 0.05, †p 0.01, ‡p 0.001.o Es
Unad
azar
Co
to a 1
1.22
1.21
1.45
1.65
1.60
1.57
0.80
1.23
1.14
1.42
1.37
0.95
0.75
1.17
4.51
2.45
1.91
5.69
1.48
1.60
1.20
facto
in raw
r from
acute
r estabisk for HF. Several previous longitudinal studies have
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Novel Risk Factors for HF December 6, 2005:2054–60hown an association between diabetes and HF (5,7,31,32).
n the present study, proinsulin—and in the secondary
nalysis excluding proinsulin, HOMA-insulin resistance—
ather than diabetes prevalence were included in the multi-
ariable models, implying that these measures of glucose
etabolism carry important risk information beyond the
iabetes diagnosis. This may indicate that the risk for HF
lready increases in the subclinical phase of impaired glucose
etabolism, better reflected in altered proinsulin and HOMA-
nsulin resistance values than in the diagnosis of diabetes.
roinsulin has been shown to be an independent long-term
redictor of CHD (33,34). It is possible that some of the
ndividuals had asymptomatic LV dysfunction at entry and
hat the insulin resistance was a consequence, not a possible
igure 1. Boxes are point estimates of multivariable Cox proportional
azards ratios (lines indicate 95% confidence intervals) for a one-standard
eviation increase of the continuous variables (fasting proinsulin, apoli-
oprotein B/A-I ratio [APOB/APOA-I], beta-carotene, and body mass
ndex) and for occurrence versus non-occurrence of dichotomous variables
hypertension, electrocardiographic left ventricular hypertrophy, and in-
erim myocardial infarction) as predictors of heart failure incidence in
iddle-aged men free from heart failure and valvular disease at baseline.
A) Variables that remained independently significant in Table 3, with the
able 3. Multivariable Cox Proportional Hazards Backward
tepwise Model, Examining the Independency of Novel and
stablished Risk Factors to HF Incidence in the Total Sample
n  2,321)
Hazard Ratio for HF
Corresponding
to a 1-SD Increase
(95% CI)
asting proinsulin (pmol/l) 1.38 (1.15–1.66)†
polipoprotein B/A-I-ratio 1.27 (1.09–1.48)*
eta-carotene (g/l) 0.79 (0.66–0.94)*
ypertension prevalence 1.70 (1.21–2.39)*
MI (kg/m2) 1.24 (1.06–1.46)*
CG-LVH 3.38 (1.55–7.34)*
ox proportional hazards ratios are given for a 1-SD increase in raw or logarithmically
ransformed variables, except for hypertension prevalence and electrocardiographic
eft ventricular hypertrophy, which are dichotomous variables where the hazard ratio
eflects a transfer from normal to abnormal. Data are hazard ratios (95% confidence
ntervals). p values 0.05 were considered significant. Variables entered into the
odel are those significant in Table 2, right column. *p  0.01, †p  0.001.
CI  confidence interval. Other abbreviations as in Table 1.v
ddition of interim myocardial infarction. (B) Subsample of subjects free
rom myocardial infarction at baseline and during follow-up.ause, of HF, which has been proposed earlier (35). On the
ther hand, there is some evidence of a direct atherogenic
ction of the proinsulin molecule, through coronary micro-
irculatory changes leading to ischemic injury. Clinical trials
ith proinsulin in diabetic patients were prematurely ter-
inated owing to an increase in MIs in subjects treated with
roinsulin (36). However, in the ULSAM cohort, increased
roinsulin levels have previously been observed to precede
V systolic dysfunction (37) independently of other cardio-
igure 2. Nelson-Aalen plots of cumulative incidence of heart failure in
he cohort, free from heart failure and valvular disease at baseline, by two
roups (above vs. below median) of fasting proinsulin (A), apolipoprotein
/A-I ratio (APOB/APOA-I) (B), and beta-carotene (C).ascular diseases, such as MI. Thus, non-atherogenic effects
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December 6, 2005:2054–60 Novel Risk Factors for HFf the proinsulin molecule or insulin resistance with direct
yocardial effects may also be of importance for develop-
ent of HF (38,39).
polipoproteins. Several studies have proposed apoli-
oproteins as a more specific alternative to low-density
ipoprotein (LDL) cholesterol as a risk marker for cardio-
ascular diseases (40–42). A recent study showed that the
POB/APOA-I ratio was a powerful independent risk
arker of fatal MI after adjustment for age, total choles-
erol, and triglycerides (43). The reason for this may be that
he APOB/APOA-I ratio also includes information on
ther atherogenic lipoproteins, such as the APOB contain-
ng very low-density lipoprotein, rich in triglycerides, as well
s APOA-I-containing HDL. As such, the ratio gives
omprehensive information on the classic risk of LDL
holesterol as well as on other important components of the
etabolic syndrome. How this ratio directly affects cardiac
erformance independently of MI is not known, but recent
tudies have shown apolipoproteins to be closely linked to
ndothelial function, a determinant of cardiac afterload
44). As an increased afterload would influence both LV
ystolic and diastolic function, effects in the vasculature
ather than a direct action on the heart might be the
echanism whereby the APOB/APOA-I ratio increases
he risk for HF.
ntioxidants. There is emerging evidence that oxidative
tress and inflammation are involved in the pathophysiology
f HF. Some prior smaller case-control studies have pointed
ut a relationship between antioxidant levels and the sever-
ty of HF (13,15). It is possible that antioxidants, such as
eta-carotene, lower the levels of free radicals, which are
mportant mediators of oxidative stress and inflammation.
owever, it is still to be investigated if beta-carotene is an
nverse marker of inflammation or possibly itself has anti-
nflammatory effects. Our results might indicate that in-
ammation could be an important part in the development
f HF, as indicated in previous studies, which have found a
elationship between various inflammatory markers and HF
11,12,45). A recent cross-sectional case-control study has
lso found that inflammatory markers and a marker of
xidative stress were significantly correlated in HF subjects
14). Furthermore, a previous report from the ULSAM
ohort showed that serum levels of beta-carotene predicted
V diastolic function after 20 years of follow-up (46).
owever, no previous longitudinal studies have shown that
ow serum levels of antioxidants, such as beta-carotene,
redict a higher risk of developing HF, independent of
stablished risk factors. Exactly what beta-carotene mea-
ures is uncertain. In addition to being a possible marker of
xidative stress, it might also reflect nutritional intake. The
erum level of beta-carotene might be considered a marker
or a high vegetable intake, reflecting a healthy lifestyle,
hich in turn could decrease the risk of HF regardless of the
ossible antioxidative effect of beta-carotene itself.
ubsamples in our study. In the subsample without sub-ects with a prior MI at baseline or MI during follow-up, webserved essentially the same point estimates for the hazard
atios as in the total sample. However, the confidence intervals
ere slightly wider, probably a result of reduced power in this
ubsample. Thus, further studies are needed to establish the
ole of these novel risk factors for non-ischemic HF.
We also performed secondary analyses with the exclusion
f fasting proinsulin in order to use the total sample. The
esults in these secondary analyses were essentially the same,
hich implies that there was no bias introduced by the
imited number of observations with insulin variables in-
luded.
trengths and limitations. The strengths of this study
nclude the large population, the long follow-up period, and
he detailed metabolic characterization of the cohort. Fur-
hermore, all HF cases were validated, limiting the inclusion
f false positive cases. There are some limitations to this
tudy. As we examined only men of the same age with a
imilar ethnic background, this study has an unknown
eneralizability to women or other age and ethnic groups.
urthermore, because this study was initiated in the 1970s
nd the HF diagnosis was based on a review of medical
ecords, it was not possible to differ between systolic and
iastolic HF because echocardiography was not available at
he time of diagnosis for many of the cases. Thus, in our
aterial it is not possible to examine whether the risk
actors are different in systolic and diastolic HF, which
ight be possible. Another limitation of the study is that we
sed the presence of an interim MI during follow-up as a
roxy for CHD. Even if this method is an established
ethod for examining “non-ischemic” HF (26,27), it would
e better to assess non-ischemic HF in a more specific way,
.g., by examining all subjects with coronary angiography.
owever, this is not a feasible option in a large, population-
ased epidemiologic study. Furthermore, we believe that the
resence of a symptomatic MI is a good proxy for CHD
ecause it includes the most advanced cases of CHD.
onclusions. In conclusion, novel variables reflecting in-
ulin resistance and dyslipidemia, together with a low
eta-carotene level, were found to predict HF indepen-
ently of established risk factors, including interim MI, in
his community-based longitudinal study of middle-aged
en. If confirmed, our observations could have large clinical
mplications because they may offer new approaches in the
revention of HF.
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